Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity

Journal of Viral Hepatitis

Volumn 16, Issue 10, 2009, Pages 738-742

  Elefsiniotis, I S ^a,d   Pavlidis, C ^b   Dimitroulopoulos, D ^c   Vezali, E ^a   Mihas, C ^a   Mariolis Sapsakos, T ^a   Koutsounas, S ^b   Paraskevas, E ^c   Saroglou, G ^a  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b National Centre for Viral Hepatitis   (Greece)

^c Agios Savvas Cancer Hospital   (Greece)

^d NONE   (Germany)

Author keywords

Ethnicity; Genotype 4; Hepatitis C; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; ETHNIC GROUPS; EUROPE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70349234307     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01134.x     Document Type: Article

References (23)

1. McHutchinson JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
2. Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996 111 : 1307 1312.
3. National Institutes of Health. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002 19 (3 1 46.
4. Hadziyannis SJ, Sette H, Morgan T et al. Peginterferon a-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004 140 : 346 355.
5. Manns MP, Mc Hutchinson JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 965.
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
7. Heathcote EJ, Shiffman ML, Cooksley GE et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343 : 1673 1680.
8. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008 47 : 1371 1383.
9. Katsoulidou A, Sypsa V, Tassopoulos NC et al. Molecular epidemiology of HCV in Greece: temporal trends in HCV genotype- specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006 13 : 19 27.
10. Savvas S, Koskinas J, Sinani C et al. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005 12 (5 551 557.
11. Diago M, Hassanein T, Rodes J et al. Optimized virologic response in HCV genotype 4 with PEG-IFNa2a and ribavirin. Ann Intern Med 2004 140 : 72 73.
12. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 699.
13. Frank C, Mohamed M, Strickland G et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt. Lancet 2000 355 : 887 891.
14. Kamal S, Madwar M, Bianchi L et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C coinfected with S. mansoni. Liver 2000 20 : 281 289.
15. Habib M, Mohamed M, Abdel-Aziz F. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001 33 : 248 253.
16. Martín-Carbonero L, Puoti M, García-Samaniego J et al. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 2008 15 (10 710 715.
17. Kamal SM, El Kamary SS, Shardell MD et al. Pegylated interferon-a2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virological response. Hepatology 2007 46 : 1732 1740.
18. Hasan F, Asker H, Al-Khaldi J et al. Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004 99 : 1733 1737.
19. Kamal SM, El Tawil AA, Nakano T et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005 54 : 858 866.
20. Roulot D, Bourcier V, Grando V et al. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007 14 : 460 467.
21. López-Alonso G, Agreda M, Devesa MJ et al. Results of the treatment of chronic hepatitis C genotype 4 - a comparative analysis with genotype 1. Rev Esp Enferm Dig 2008 100 (4 208 211.
22. Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a Spanish center. J Chemother 2007 19 (4 423 427.
23. El-Zayadi AR, Attia M, Barakat EMF et al. Response of HCV genotype 4 naïve patients to 24 weeks of PEG-IFNa2b/ribavirin or induction dose IFNa2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005 100 : 2447 2452.